DNA Analysis in Influencing Response to Rituximab in Samples From Patients With Follicular Lymphoma Treated on ECOG-E4402

Sponsor
Eastern Cooperative Oncology Group
Study ID
NCT01406782
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 120 Years
Healthy Volunteers
Not accepted

Interventions

  • rituximab — BIOLOGICAL
  • DNA analysis — GENETIC
  • gene expression analysis — GENETIC
  • polymerase chain reaction — GENETIC
  • laboratory biomarker analysis — OTHER

Study Details

RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how well patients will respond to treatment. PURPOSE: This research study is studying DNA isolated from blood samples to see how well it influences response to rituximab in patients with follicular lymphoma treated on clinical trial ECOG-E4402.

Key Dates

Start date
Dec 13, 2011
Status verified
May 2017
Primary completion
Jan 13, 2012
Completion
Jan 13, 2012

Study Design

Enrollment
200 participants (actual)

Primary Outcome Measure

KIR-HLA genotype predictive of antibody-dependent cell-mediated cytotoxicity (ADCC)-based cancer immunotherapy [ Time Frame: 1 year ]

Related Studies